Brief: Piramal Pharma Says US FDA Conducted Gmp Inspection Of Co's Bethlehem Facility From Sept 18 To Sept 27
28/09/2023 14:54
Sept 28 (Reuters) - Piramal Pharma Ltd PIRM.NS :
* US FDA CONDUCTED GMP INSPECTION OF CO'S BETHLEHEM FACILITY
FROM
SEPT 18 TO SEPT 27
* ON CONCLUSION OF INSPECTION, A FORM-483 WAS ISSUED WITH 2
OBSERVATIONS
Source text for Eikon: ID:nBSE3dDMh5
Further company coverage: PIRM.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma (Mumbai) Says Commercial Arrangement With Bayer Pharmaceuticals To Expire On December 31, 2026
Brief: Piramal Pharma (Mumbai) Says Tax Authority Confirms Demand Of 40.6 Million Rupees And Imposes Equivalent Penalty
India's Piramal Pharma falls after US FDA observations at UK facility
Brief: Piramal Pharma Says US FDA Issues Form-483 With 7 Observations To Morpeth UK Facility
Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio